Cell Therapeutics' Special Meeting of Shareholders adjourned to June 4, 2010

Download PDF Copy

Editorial Checklist

Reviewed

Cell Therapeutics, Inc.May 15 2010

NewsGuard 100/100 Score

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that the Company has adjourned today's Special Meeting of Shareholders (the "Special Meeting") to 10:00 am Pacific Daylight Time, Friday, June 4, 2010.

The Company's proxy materials previously filed with the Securities and Exchange Commission (the "SEC") on February 23, 2010 and the proposals being submitted to a vote of the shareholders at the Special Meeting as described in such proxy materials remain unchanged. The Company encourages those shareholders that held shares as of February 19, 2010, the record date of the Special Meeting, to vote their shares on the proposals.

Source:

Cell Therapeutics, Inc.

Posted in:

Tags: B Cell, Biotechnology, Cell, Oncology, Rotarix, Rotavirus, T-Cell, Therapeutics, Vaccine

Comments (0)

Download PDF Copy

Suggested Reading

Neuropeptides influence T cell differentiation during viral infections

Neuropeptides influence T cell differentiation during viral infections

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Liver cell aging can trigger multi-organ failure

Liver cell aging can trigger multi-organ failure

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Barcoding small extracellular vesicles with new CRISPR-based system